Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?

@article{Tennant2003LongactingB2,
  title={Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?},
  author={Rachel C. Tennant and Edward M Erin and Peter J Barnes and Trevor T. Hansel},
  journal={Current opinion in pharmacology},
  year={2003},
  volume={3 3},
  pages={270-6}
}
Bronchodilators are the mainstay of therapy for patients with established chronic obstructive pulmonary disease (COPD) but, at present, the majority of patients use short-acting agents. There is increasing evidence that long-acting agents, such as the beta(2)-adrenoceptor agonists salmeterol and formeterol, and the new anticholinergic tiotropium bromide provide a better therapeutic option. In the treatment of COPD, long-acting beta(2)-adrenoceptor agonists (LABAs) given twice daily cause the… CONTINUE READING